Frontiers in Genetics, Год журнала: 2024, Номер 15
Опубликована: Ноя. 12, 2024
The fusion gene is a rare form of α-thalassemia. Patients carrying the could be misdiagnosed as normal or -α
Язык: Английский
Journal of Hematology & Oncology, Год журнала: 2024, Номер 17(1)
Опубликована: Окт. 10, 2024
Pancreatic cancer remains one of the most aggressive solid tumors. As a systemic disease, despite improvement multi-modality treatment strategies, prognosis pancreatic was not improved dramatically. For resectable or borderline patients, surgical strategy centered on improving R0 resection rate is consensus; however, role neoadjuvant therapy in patients and optimal chemotherapy with without radiotherapy were debated. Postoperative adjuvant gemcitabine/capecitabine mFOLFIRINOX recommended regardless margin status. Chemotherapy as first-line for advanced metastatic included FOLFIRINOX, gemcitabine/nab-paclitaxel, NALIRIFOX regimens whereas 5-FU plus liposomal irinotecan only standard care second-line therapy. Immunotherapy an innovative although anti-PD-1 antibody currently agent approved by MSI-H, dMMR, TMB-high tumors, which represent very small subset cancers. Combination strategies to increase immunogenicity overcome immunosuppressive tumor microenvironment may sensitize immunotherapy. Targeted therapies represented PARP KRAS inhibitors are also under investigation, showing benefits progression-free survival objective response rate. This review discusses current modalities highlights cancer.
Язык: Английский
Процитировано
21
American Society of Clinical Oncology Educational Book, Год журнала: 2025, Номер 45(3)
Опубликована: Апрель 2, 2025
Pancreatic adenocarcinoma remains one of the most aggressive and difficult-to-treat solid tumor malignancies, with a high mortality-to-incidence ratio. Globally, pancreatic cancer ranks 12th in terms incidence but sixth for mortality signifying its behavior limited treatment options. While rates many other tumors have substantially improved over past few decades, temporal trends are quite sobering. In United States, from 2000 to 2020, increased, whereas at same time, cancers, such as lung, colorectal, or kidney, fallen appreciably. Is this lack innovation? How do we improve survival patients cancer? chapter, discuss recent advances future directions targeted therapies immunotherapies cancer, provide reasons both optimism caution systemic cancer.
Язык: Английский
Процитировано
1
Modern Pathology, Год журнала: 2024, Номер 37(9), С. 100554 - 100554
Опубликована: Июнь 29, 2024
Язык: Английский
Процитировано
3
Japanese Journal of Clinical Oncology, Год журнала: 2025, Номер unknown
Опубликована: Фев. 2, 2025
Abstract Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis; however, advancements in cancer genome profiling using next-generation sequencing have provided new perspectives. KRAS mutations are the most frequently observed genomic alterations patients with PDAC. However, until recently, it was not considered viable therapeutic target. Although G12C for which targeted therapies already available infrequent PDAC, treatments targeting G12D and pan-KRAS still under development. Similarly, treatment methods KRAS, such as chimeric antigen receptor T-cell therapy, been developed. Several other potential targets identified wild-type For instance, immune checkpoint inhibitors demonstrated efficacy PDAC microsatellite instability-high/deficient mismatch repair tumor mutation burden–high profiles. cases low immunogenicity, combination that enhance effectiveness of being considered. Additionally, homologous recombination deficiencies, including BRCA1/2 mutations, prevalent serve important biomarkers involving poly (adenosine diphosphate-ribose) polymerase platinum-based therapies. Currently, olaparib is maintenance therapy mutation-positive Further developments ongoing genetic abnormalities BRAF V600E fusion genes RET, NTRK, NRG, ALK, FGFR2, ROS1. Overcoming advanced remains formidable challenge; this review outlines latest strategies expected to lead significant advancements.
Язык: Английский
Процитировано
0
Future Oncology, Год журнала: 2025, Номер unknown, С. 1 - 12
Опубликована: Март 24, 2025
Gene fusions represent important oncogenic driver mutations resulting in aberrant cellular signaling. In up to 17% of all solid tumors at least one gene fusion can be identified. Precision therapy targeting signaling has demonstrated effective clinical benefit. Advancements clinically relevant next-generation sequencing and bioinformatic techniques have enabled expansion therapeutic opportunity subpopulations patients with expression. Clinically, tyrosine inhibitors shown efficacy treating expressing cancers. Fusion genes are also clonal mutations, meaning it is a personal cancer target involving cells that patient, not just subpopulation within the mass. Thus, both signal disruption immune directions. This review discusses targeting, resistance, molecular biomarkers.
Язык: Английский
Процитировано
0
ESMO Gastrointestinal Oncology, Год журнала: 2025, Номер 8, С. 100179 - 100179
Опубликована: Май 20, 2025
Язык: Английский
Процитировано
0
Biophysical Reviews, Год журнала: 2025, Номер unknown
Опубликована: Май 31, 2025
Язык: Английский
Процитировано
0
International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(21), С. 11560 - 11560
Опубликована: Окт. 28, 2024
Pancreatic cancer remains one of the deadliest malignancies, with a consistently low five-year survival rate for past several decades. This is in stark contrast to other cancers, which have seen significant improvement and prognosis due recent developments therapeutic modalities. These modest improvements pancreatic outcomes primarily resulted from minor advances cytotoxic chemotherapeutics, limited progress treatment approaches. A major focus current research further development immunomodulatory therapies characterized by antibody-based approaches, cellular therapies, vaccines. Although initial results utilizing immunotherapy been mixed, clinical trials demonstrated patient outcomes. In this review, we detail these three approaches immunomodulation, highlighting their common targets distinct shortcomings, provide narrative summary completed ongoing that utilize immunomodulation. Within context, aim inform future efforts identifying promising areas warrant exploration.
Язык: Английский
Процитировано
2
Targeted Oncology, Год журнала: 2024, Номер 19(5), С. 679 - 689
Опубликована: Авг. 10, 2024
Язык: Английский
Процитировано
1
Carcinogenesis, Год журнала: 2024, Номер 45(11), С. 836 - 844
Опубликована: Ноя. 1, 2024
Abstract Precision oncology and tumor-agnostic drug development provide hope for enhancing outcomes among patients with pancreatic cancer. Tumor-agnostic therapies have emerged across various tumor types, driven by insights into shared biomarkers. In the case of cancer, prevalence KRAS gene mutation is noteworthy. However, there exist other actionable alterations, such as BRCA1/2 mutations fusion genes (BRAF, FGFR2, RET, NTRK, NRG1, ALK), which present potential targets therapy. Notably, drugs demonstrated efficacy in specific subsets cancer who harbor these genetic alterations. Despite rarity NTRK fusions larotrectinib entrectinib exhibited effectiveness fusion-positive cancers. Additionally, repotrectinib, a next-generation inhibitor, has shown promising activity positive developed acquired resistance to previous inhibitors. Immune checkpoint inhibitors, pembrolizumab dostarlimab, proven be effective dMMR/MSI-H Moreover, targeted BRAF V600, RET fusions, HER2/neu overexpression displayed results patients. Emerging like NRG FGFR2 TP53 mutations, G12C avenues revolutionize treatment focusing on It crucial continue implementing comprehensive screening strategies that encompass ability detect all This will essential identifying may benefit from therapies.
Язык: Английский
Процитировано
1